median follow up from the first venous thromboembolic episode was 93 months and the median age at this episode was 26 years. The patients had in total 34 venous thromboembolic episodes. The total follow up period comprised 32 periods with and 23 periods without anticoagulant drugs. Results-The probability of being free of recurrent venous thromboembolic episodes, calculated by the Kaplan-Meier method, was significantly influenced by the use of anticoagulant drugs. Patients receiving oral anticoagulants had at eight years a 100% probability of survival without recurrence, whereas patients in whom anticoagulant drugs were stopped had a 50% probability of a recurrent venous thromboembolic episode at two years, and a 78% probability ofrecurrence at eight years. Conclusion 28 months (range 11-101 months) in those with a single episode (seven patients).
During the follow up period arterial thrombosis occurred in three patients (thrombosis of the distal aorta in patient 1 and myocardial infarction in patients 3 and 4). In patients 3 and 4 myocardial infarction occurred during adequate treatment with oral anticoagulants (international normalised ratio at admission 3-6 and 2-6 respectively).
In all but one patient (patient 18) the follow up period could be divided into periods with and without treatment with oral anticoagulants. All patients had normal levels of antithrombin III, protein C, and protein S. None had erythrocytosis, thrombocytosis, or a malignancy.
Oral contraceptives containing oestrogen were used at the time of 11/34 venous thromboembolic episodes in 10 patients. The ethinyloestradiol content of the birth control pills was 0 05 mg in two, 0 0375 mg in two, and 0-03 mg in seven episodes.
Active SLE (nephrotic syndrome in two, non-infectious fever in one patient) was present at the time of 3/17 venous thromboembolic episodes that occurred after a diagnosis of SLE was made. Two of these three venous thromboembolic episodes were also related to immobilisation. None of the other episodes was associated with immobilisation or an intercurrent illness. A total of 4/34 venous thromboembolic episodes in four different patients were related to pregnancy. One occurred at a gestational age of 13 weeks; the other three were within the six week postpartum period.
In 17/34 venous thromboembolic episodes no additional risk factors could be found. In 10/12 patients with recurrent venous thromboembolic episodes, at least one episode occurred in the absence of additional risk factors.
Discussion
Our study shows that patients with a venous thromboembolic episode and antiphospholipid antibodies have an extremely high risk for recurrent venous thrombosis after withdrawal of treatment with oral anticoagulants. Most of the recurrences occur within the first year after the withdrawal of anticoagulant drugs, as indicated by a probability of venous thromboembolic episode-free survival at one year of 55% (fig 2) . At eight years the probability of being free of recurrent venous That study concluded that recurrent thrombosis is a potentially serious problem for patients with antiphospholipid antibodies and that warfarin prophylaxis with an international normalised ratio greater than 2 6 is effective. These observations also correspond to those from Asherson et al,3 who considered inadequate treatment with warfarin (international normalised ratio between 2 and 2-5) to be responsible for recurrent thrombotic events in 4/9 patients with antiphospholipid syndrome in a five year follow up study.
Long term treatment with oral anticoagulants given at a high therapeutic level is not without risks, as is illustrated by the two serious bleeding complications we encountered in 19 patients. In our opinion this risk should be taken, given the high risk of potentially fatal venous thromboembolic episodes in these young patients. From our study it cannot be excluded that less intense treatment with anticoagulant drugs might also be effective, but other data12 13 suggest that anticoagulation at an international normalised ratio less than 2-0 is an inadequate prophylaxis for these patients.
From this study we conclude that continuation of treatment with oral anticoagulants is indicated in patients who have had a venous thrombosis and in whom antiphospholipid antibodies are repeatedly found. Although our study has the drawback of being retrospective, we changed our policy completely once these data were available. We feel that awaiting the results of prospective randomised trials would leave an important risk group unprotected for an unacceptable period of time. Prospective studies to define precisely the rate of occurrence of repeated thrombosis in unselected patients are urgently needed, however, to determine whether our treatment strategy can be generalised. 
